Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Testa U, Castelli G, Pelosi E.

Medicines (Basel). 2019 Jul 30;6(3). pii: E82. doi: 10.3390/medicines6030082. Review.

2.

Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism.

Castelli G, Pelosi E, Testa U.

Cancers (Basel). 2019 Feb 22;11(2). pii: E260. doi: 10.3390/cancers11020260. Review.

3.

The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.

Spinello I, Saulle E, Quaranta MT, Pasquini L, Pelosi E, Castelli G, Ottone T, Voso MT, Testa U, Labbaye C.

Haematologica. 2019 May;104(5):973-985. doi: 10.3324/haematol.2018.199661. Epub 2018 Nov 22.

4.

Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors.

Testa U, Castelli G, Pelosi E.

Med Sci (Basel). 2018 Oct 2;6(4). pii: E85. doi: 10.3390/medsci6040085. Review.

5.

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Testa U, Castelli G, Pelosi E.

Cancers (Basel). 2018 Jul 27;10(8). pii: E248. doi: 10.3390/cancers10080248. Review.

6.

miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development.

Testa U, Pelosi E, Castelli G, Labbaye C.

Noncoding RNA. 2017 Jun 26;3(3). pii: E22. doi: 10.3390/ncrna3030022. Review.

7.

Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Testa U, Pelosi E, Castelli G.

Med Sci (Basel). 2018 Apr 13;6(2). pii: E31. doi: 10.3390/medsci6020031. Review.

8.

Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E.

Medicines (Basel). 2018 Feb 1;5(1). pii: E16. doi: 10.3390/medicines5010016. Review.

9.

Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.

Castelli G, Pelosi E, Testa U.

Onco Targets Ther. 2017 Dec 28;11:131-155. doi: 10.2147/OTT.S145971. eCollection 2018. Review.

10.

Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Testa U, Castelli G, Pelosi E.

Med Sci (Basel). 2017 Nov 20;5(4). pii: E28. doi: 10.3390/medsci5040028. Review.

11.

Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

Pelosi E, Castelli G, Testa U.

Biomedicines. 2017 Nov 18;5(4). pii: E65. doi: 10.3390/biomedicines5040065. Review.

12.

Mechanisms of anti-cancer effects of ascorbate: Cytotoxic activity and epigenetic modulation.

Mastrangelo D, Pelosi E, Castelli G, Lo-Coco F, Testa U.

Blood Cells Mol Dis. 2018 Mar;69:57-64. doi: 10.1016/j.bcmd.2017.09.005. Epub 2017 Sep 21. Review.

PMID:
28954710
13.

Esophageal Cancer: Genomic and Molecular Characterization, Stem Cell Compartment and Clonal Evolution.

Testa U, Castelli G, Pelosi E.

Medicines (Basel). 2017 Sep 14;4(3). pii: E67. doi: 10.3390/medicines4030067. Review.

14.

Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.

Castelli G, Pelosi E, Testa U.

Cancers (Basel). 2017 Sep 20;9(9). pii: E127. doi: 10.3390/cancers9090127. Review.

15.

High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.

Noguera NI, Pelosi E, Angelini DF, Piredda ML, Guerrera G, Piras E, Battistini L, Massai L, Berardi A, Catalano G, Cicconi L, Castelli G, D'AngiĆ² A, Pasquini L, Graziani G, Fioritoni G, Voso MT, Mastrangelo D, Testa U, Lo-Coco F.

Oncotarget. 2017 May 16;8(20):32550-32565. doi: 10.18632/oncotarget.15925.

16.

Targeted therapies in the treatment of adult acute myeloid leukemias: current status and future perspectives.

Castelli G, Pelosi E, Testa U.

Int J Hematol Oncol. 2016 Dec;5(4):143-164. doi: 10.2217/ijh-2016-0011. Epub 2017 Feb 7. Review.

17.

Conditioned medium from human umbilical vein endothelial cells markedly improves the proliferation and differentiation of circulating endothelial progenitors.

Castelli G, Parolini I, Cerio AM, D'AngiĆ² A, Pasquini L, Carollo M, Sargiacomo M, Testa U, Pelosi E.

Blood Cells Mol Dis. 2016 Oct;61:58-65. doi: 10.1016/j.bcmd.2016.07.007. Epub 2016 Aug 18.

PMID:
27667168
18.

Endothelial progenitor cells in hematologic malignancies.

Testa U, Saulle E, Castelli G, Pelosi E.

Stem Cell Investig. 2016 Jul 1;3:26. doi: 10.21037/sci.2016.06.07. eCollection 2016. Review.

19.

Oxidative stress and hypoxia in normal and leukemic stem cells.

Testa U, Labbaye C, Castelli G, Pelosi E.

Exp Hematol. 2016 Jul;44(7):540-60. doi: 10.1016/j.exphem.2016.04.012. Epub 2016 May 12. Review.

PMID:
27179622
20.

Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.

Pelosi E, Castelli G, Testa U.

Blood Cells Mol Dis. 2015 Dec;55(4):336-46. doi: 10.1016/j.bcmd.2015.07.015. Epub 2015 Jul 26. Review.

PMID:
26460257

Supplemental Content

Loading ...
Support Center